These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 35650458)

  • 1. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
    Cohen F; Yuan H; Silberstein SD
    BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.